STUDY OF MK0677 IN GROWTH IN HORMONE DEFICIENCY

MK0677 在激素缺乏症中生长的研究

• 批准号: 6291182
• 负责人: Ora H Pescovitz
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291182
• 关键词: blood chemistry; child (0-11); child physical development; clinical research; clinical trials; dosage; drug adverse effect; drug screening /evaluation; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; oral administration; pituitary gland; somatotropin

Growth hormone is important for normal growth and development in childhood. A lack of growth hormone in children is currently treated by human recombinant growth hormone that must be given daily by an injection under the skin. MK-0677 is a new drug which caused growth hormone release after oral administration. The purpose of this study is to evaluate the effectiveness of MK-0677 in increasing growth velocity in GH-deficient children; to evaluate the safety and tolerability of MK-0677; and to measure the release of GH and other hormones as well as MK-0677 blood levels following administration of MK-0677 to GH-deficient children. The present study will also assist in the selection of a dosage regimen for subsequent studies.

生长激素对于儿童时期的正常生长和发育很重要。目前，儿童生长激素缺乏症的治疗方法是人类重组生长激素，必须每天皮下注射。 MK-0677是一种口服后引起生长激素释放的新药。 本研究的目的是评估 MK-0677 在提高 GH 缺乏儿童生长速度方面的有效性；评估MK-0677的安全性和耐受性；并测量 GH 缺乏儿童服用 MK-0677 后 GH 和其他激素的释放以及 MK-0677 血液水平。 本研究还将有助于选择后续研究的剂量方案。